Navigation Links
Canadian biomedical engineering pioneer receives international award
Date:4/23/2009

Countless individuals around the world are alive because of him. His 40 plus years of research have helped to make the use of life-saving devices such as prosthetic heart valves, vascular stents, vascular grafts, heart-assist devices, and heart-lung bypass systems almost commonplace. In the process, he has helped to establish Canada as a biomaterials leader.

John Brash, P.Eng., director of the School of Biomedical Engineering at McMaster University, and distinguished university professor, was recognized for these contributions with the presentation of the Founders Award by the Society for Biomaterials on April 22 in San Antonio, Texas.

"I am honoured and humbled to receive this award given the calibre of past recipients," said Prof. Brash. "It was a surprise when I was notified of the award. Much of the recognition must be shared with the numerous colleagues, peers, and students I have been fortunate to have worked with over the years."

Prof. Brash is only the second Canadian to receive this award, of which just 14 have been presented since it was established in 1987. Michael Sefton, university professor of chemical engineering and applied chemistry, University of Toronto, received the award in 2008. Selection for a Founders Award is based on long-term, landmark contributions to the discipline of biomaterials.

"John has been a leading member of the world's biomaterials community for many years," said Michael Sefton, past-president of the Society for Biomaterials and chair of the awards committee. "His seminal contributions to our understanding of the behaviour of proteins at interfaces and to the use of polyurethanes in medicine have been among the most important and long-standing contributions to the science of biomaterials."

Prof. Brash is internationally regarded for his work in at least three major areas: protein adsorption and blood compatibility, particularly as it relates to blood proteins and thrombus formation on artificial surfaces; biocompatible polyurethane based materials; and surface modification.

"His literature contributions have guided the work of countless biomaterials scientists," said Heather Sheardown, associate professor of chemical engineering at McMaster. "Another of John's important contributions is in the training of a new generation of biomaterials scientists who have gone on to work in academia and industry, continuing to advance the field and carrying with them a passion ignited during their time in the Brash lab."

Prof. Brash has trained some 50 Masters, PhDs and postdoctoral fellows. He is also called on to consult with numerous biomaterials-related companies.

"Dr. Brash, whether interacting with fellow chemical engineers, biomaterials scientists or clinicians, has had a significant influence on the evolution of the field of biomaterials," said Stuart Cooper, professor and chair of the department of chemical and biomolecular engineering, at Ohio State University.

Discoveries by Prof. Brash can be found in some of Canada's most successful biomedical companies including Interface Biologics Inc. of Toronto and Angiotech Inc. in Vancouver.

"The latter part of the 80s and early 90s ushered in the concept of designing biomaterials that were pro-active in their interaction with proteins and cells," explains Prof. Santerre, who is also chief scientific officer and co-founder of Interface Biologics. "John's program in polyurethane research was among the first to build-in functional monomers that would capitalize on simulating the natural mechanisms of anti-coagulant function. Today, the bioactive concept is revolutionizing medical devices by merging the biopharmaceutical field and medical device sector to deliver implant therapies that accelerate healing associated with serious diseases."


'/>"/>

Contact: Gene Nakonechny
genen@mcmaster.ca
905-525-9140 x26781
McMaster University
Source:Eurekalert

Related biology news :

1. Ancient organisms discovered in Canadian gold mine
2. Canadian Society of Exercise Physiology Annual Scientific Conference
3. Massive Canadian oilfield could be exploited using new UK system
4. First images from medical beamline at Canadian Light Source
5. Canadian scientist mines drugs database for new diabetes treatment
6. Fossil evidence of missing link in the origin of seals, sea lions, walruses found in Canadian Arctic
7. Boston University biomedical engineers find chink in bacterias armor
8. $22 million gift from Alfred Taubman launches new biomedical research institute
9. USC biomedical team to participate in $6 million low vision project
10. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
11. UVa biomedical engineering study shows magnetic field can reduce swelling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... CAMBRIDGE, Mass. , Jan. 21, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 American Society ... San Francisco . In ... administered investigational agent designed to inhibit cancer stemness pathways ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo ... of Gen9, a pioneer in the synthesis and ... unique expertise in assembling pathway-length synthetic DNA into ... and capacity in the construction of new organism ... industries. "Gen9 was founded to significantly ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
Breaking Biology Technology: